AIM: To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients. METHODS: An open-label, randomized, crossover study. Patients received Treatment A [NVP 200 mg b.i.d. plus > or =2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] and Treatment B [A plus DRV/r 300/100 mg b.i.d. (DRV oral solution)] or Treatment B2 [A plus DRV/r 400/100 mg b.i.d. (DRV tablet)] in two 14-day sessions. RESULTS:Mean NVP AUC(12h) increased by 27% [least square means ratio 1.27 (95% confidence interval 1.02, 1.58)]. Mean DRV and ritonavir exposures were similar to historical data. Co-administration was well tolerated. CONCLUSIONS: DRV/r and NVP have no clinically relevant interaction. No dose adjustments are required.
RCT Entities:
AIM: To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infectedpatients. METHODS: An open-label, randomized, crossover study. Patients received Treatment A [NVP 200 mg b.i.d. plus > or =2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] and Treatment B [A plus DRV/r 300/100 mg b.i.d. (DRV oral solution)] or Treatment B2 [A plus DRV/r 400/100 mg b.i.d. (DRV tablet)] in two 14-day sessions. RESULTS: Mean NVP AUC(12h) increased by 27% [least square means ratio 1.27 (95% confidence interval 1.02, 1.58)]. Mean DRV and ritonavir exposures were similar to historical data. Co-administration was well tolerated. CONCLUSIONS: DRV/r and NVP have no clinically relevant interaction. No dose adjustments are required.
Authors: José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banhegyi; Kiat Ruxrungtham; Dorece Norris; Eric Lefebvre; Marie-Pierre de Béthune; Frank Tomaka; Martine De Pauw; Tony Vangeneugden; Sabrina Spinosa-Guzman Journal: Lancet Date: 2007-07-07 Impact factor: 79.321
Authors: T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191
Authors: Vanitha Sekar; Ludo Lavreys; Tom Van de Casteele; Cindy Berckmans; Sabrina Spinosa-Guzman; Tony Vangeneugden; Martine De Pauw; Richard Hoetelmans Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191
Authors: Clifford G Banda; Fraction Dzinjalamala; Mavuto Mukaka; Jane Mallewa; Victor Maiden; Dianne J Terlouw; David G Lalloo; Saye H Khoo; Victor Mwapasa Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Clifford G Banda; Fraction Dzinjalamala; Mavuto Mukaka; Jane Mallewa; Victor Maiden; Dianne J Terlouw; David G Lalloo; Saye H Khoo; Victor Mwapasa Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191